🔎Another look at the publication of results from our #PROWES trial. A major milestone supporting #EpiSwitchCiRT’s role in guiding #cancer #immunotherapy, and validating its real-world impact on clinical decision-making: 🔗 https://t.co/8nZfPdtlzI #Oncology #OBD @OxBioDynamics

Grateful to Dr Kashyap Patel for leading the #EpiSwitchCiRT study, prioritising better patient #immunotherapy outcomes. His work shows how community oncologists can turn innovation into improved care. Thanks @oncodaily for sharing this perspective. 🔗 https://t.co/m6SIvSxVSg #OBD

Immunotherapy has transformed cancer care. During National Cancer Research Month, we’re spotlighting how tools like EpiSwitch® CiRT are helping move us toward more precise, personalized treatments. Learn more: https://t.co/v8t99k9iOr. #NationalCancerResearchMonth #NCRM25

Take home messages from @RebeccaDSing on immunotherapy in early TNBC #ESMOBreast25 #ESMOAmbassadors @myESMO

An enthusiast and militant talk by @lab_kok at #ESMOBreast25 on the importance of developing better biomarkers for immunotherapy in breast cancer, highlighting among others the KN522 example #ESMOAmbassadors @myESMO

In her Keynote Lecture at #ESMOBreast25, @LoiSher considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups Full article in the #ESMODailyReporter https://t.co/9grU7MQYKZ

No biomarkers for ICI efficacy in early Tnbc Marleen Kok #ESMOAmbassadors #ESMOBreast25 @myESMO

🧬 Predicting patient response to immunotherapy is a game-changer! At CB & CDx Summit Europe, our CSO Alexandre Akoulitchev highlighted the power of EpiSwitch® CiRT, a blood test that predicts response to immune checkpoint inhibitors (ICIs) with unmatched accuracy. 💡 Key

OBD's Dr. Ryan Mathis and Dr. Bartu Ahiska took center stage at the virtual UK National IO Education Forum to discuss the clinical utility of the EpiSwitch CiRT checkpoint inhibitor response test. This forum, attended by ~100 multidisciplinary team (MDT) members who manage

Grateful to present our work on @EpiSwitchCiRT at #ASCOGI2025! We showed how this blood test can predict immunotherapy responses in GI cancers. High probability responders had longer PFS (p=0.044), showing great clinical potential. Great collaboration with @OxBioDynamics team!

For many patients with advanced #LiverCancer, there’s only one shot at effective treatment. With half never reaching second-line therapy, precision tools like #EpiSwitchCiRT help doctors make informed, first-line decisions—maximizing survival and improving patient outcomes. Read

📢 We’re excited to announce our data package (abstract #623) will be presented at @ASCO #GI25 this week. 📝 Evaluation of EpiSwitch in predicting immunotherapy response in hepatocellular carcinoma and gastrointestinal tumors. In collaboration with @gumedcenter, this study

Patients with advanced #livercancer face limited treatment options and uncertain outcomes. Learn how doctors are utilizing #precisionmedicine with tools like EpiSwitch® CiRT to optimize patient management strategies. Read more in our latest #InTheLoop blog post:

Excited to share that our abstract with @EpiSwitchCiRT, Evaluation of EpiSwitch in predicting immunotherapy response in hepatocellular carcinoma and gastrointestinal tumors, has been accepted for poster presentation at @ASCO #GI25! Huge thanks to @OxBioDynamics for the

Curious about EpiSwitch® CiRT’s role in cancer care? Hear about our first-of-its-kind blood test that helps predict immunotherapy response in the @immunobuddies podcast with @RickyFrazer1 & @AOlssonBrown. Learn more in our latest #InTheLoop blog post: https://t.co/ysOp2XvJhr.

Proud to see EpiSwitch® CiRT featured in @HandPnews’s article about healthcare provider @bupauk. Our test supports clinicians in determining the effectiveness of immunotherapy for cancer patients. Discover how genomics is transforming patient care at Bupa. #Cancer #Immunotherapy